Bristol Myers: Value or Trap?

Bristol Myers Squibbs stock, currently around $60, presents a potential value play for investors, despite patent expirations threatening its top earners, Opdivo and Eliquis. The companys growth pipeline is robust, with Reblozyl sales surging and Qvantig (subcutaneous Opdivo) skyrocketing. The portfolios revenue hit $6.2 billion, a 12% year-over-year increase. Investors are divided, with some seeing a value trap and others finding a bargain at 9x forward earnings and a 4.5% dividend yield. The companys pipeline, including Milvexian and Pumitamig, adds to its appeal. Overall, Bristol Myers Squibb appears to be a smart medium-term bet for value hunters and dividend chasers. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3abb243375d6cd5d